CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLRs), today announced the formation of an Autoimmune Disease Scientific Advisory Board.
